HPV & head and neck cancer: a descriptive update.

Simple item page
dc.creatorGoon, Peter KC
dc.creatorStanley, Margaret A
dc.creatorEbmeyer, Jörg
dc.creatorSteinsträsser, Lars
dc.creatorUpile, Tahwinder
dc.creatorJerjes, Waseem
dc.creatorBernal-Sprekelsen, Manuel
dc.creatorGörner, Martin
dc.creatorSudhoff, Holger H
dc.date2011-06-16T16:13:30Z
dc.date2011-06-16T16:13:30Z
dc.date2009-10-14
dc.date2011-06-16T16:13:30Z
dc.date.accessioned2026-08-03T03:19:17Z
dc.descriptionThe incidence of head and neck squamous cell carcinoma (HNSCC) has been gradually increasing over the last three decades. Recent data have now attributed a viral aetiology to a subset of head and neck cancers. Several studies indicate that oral human papillomavirus (HPV) infection is likely to be sexually acquired. The dominance of HPV 16 in HPV+ HNSCC is even greater than that seen in cervical carcinoma of total worldwide cases. Strong evidence suggests that HPV+ status is an important prognostic factor associated with a favourable outcome in head and neck cancers. Approximately 30 to 40% of HNSCC patients with present with early stage I/II disease. These patients are treated with curative intent using single modality treatments either radiation or surgery alone. A non-operative approach is favored for patients in which surgery followed by either radiation alone or radiochemotherapy may lead to severe functional impairment. Cetuximab, a humanized mouse anti-EGFR IgG1 monoclonal antibody, improved locoregional control and overall survival in combination with radiotherapy in locally advanced tumours but at the cost of some increased cardiac morbidity and mortality. Finally, the improved prognosis and treatment responses to chemotherapy and radiotherapy by HPV+ tumours may suggest that HPV status detection is required to better plan and individualize patient treatment regimes.
dc.descriptionRIGHTS : This article is licensed under the BioMed Central licence at http://www.biomedcentral.com/about/license which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display the work; make derivative works; or make commercial use of the work - under the following conditions: the original author must be given credit; for any reuse or distribution, it must be made clear to others what the license terms of this work are.
dc.formattext/xml
dc.formatapplication/pdf
dc.identifierHead & Neck Oncology 2009, 1:36
dc.identifier1758-3284
dc.identifierhttp://www.dspace.cam.ac.uk/handle/1810/237900
dc.identifier1758-3284
dc.identifier.urihttps://repo.dare.co.zw/handle/123456789/175283
dc.languageEnglish
dc.languageeng
dc.publisherSpringer Nature
dc.publisherhttps://doi.org/10.1186/1758-3284-1-36
dc.rightsGoon et al.; licensee BioMed Central Ltd.
dc.subjectCarcinoma, Squamous Cell
dc.subjectCombined Modality Therapy
dc.subjectErbB Receptors
dc.subjectHead and Neck Neoplasms
dc.subjectHuman papillomavirus 16
dc.subjectHumans
dc.subjectNeoplasm Recurrence, Local
dc.subjectPapillomavirus Infections
dc.subjectRisk Factors
dc.subjectViral Load
dc.subjectVirus Integration
dc.titleHPV & head and neck cancer: a descriptive update.
dc.typeArticle

Files

Collections

University of Cambridge Apollo